Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
ClonoSEQ Cleared for Residual Cancer Testing
Home
Publications
ClonoSEQ Cleared for Residual Cancer Testing
ClonoSEQ Cleared for Residual Cancer Testing
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Publisher website
Google Scholar
1 December 2018
journal article
Published by
American Association for Cancer Research (AACR)
in
Cancer Discovery
Vol. 8
(12)
,
OF6
DOI:
10.1158/2159-8290.cd-nb2018-136
PMID:
30327352
Abstract
The FDA granted marketing authorization to the first-ever next-generation sequencing assay for detecting minimal residual disease in patients with acute lymphoblastic leukemia or multiple myeloma.
Keywords
CANCER TESTING
CLONOSEQ CLEARED
RESIDUAL CANCER
FDA GRANTED
MULTIPLE MYELOMA
MINIMAL RESIDUAL
RESIDUAL DISEASE
GRANTED MARKETING
MARKETING AUTHORIZATION
FIRST-EVER NEXT-GENERATION
Related articles
Cited
Cited by 20 articles
Scroll to top